HITTING THE TARGET: Multigene Tests Gain Foothold in More Clinical Settings Broad adoption of testing methods that allow for assessing all possible actionable targets and diagnostic markers in advanced cancer is becoming more complex with greater availability of lifesaving targeted therapies. | Jun 29, 2020
PGDx Applies CE Mark to Second Cancer Assay Clinical OMICs | Sep 25, 2019
Liquid biopsy test detects MSI status, TMB Biocentury | Sep 12, 2019
PGDx Liquid Biopsy Assay Gets CE Marking GenomeWeb | Mar 14, 2019